Sun Pharma Share Price Fall 5% Despite Strong Market: Key Reasons Behind the Decline

Sun Pharmaceutical Industries share price fell around 5% even as the broader market remained strong. The stock slipped to around ₹1,630–₹1,650 during the session as investors booked profits and reacted to fresh developments.

Organon Acquisition Buzz Worries Investors

One of the main reasons for the fall is the company’s reported move toward a $12-billion acquisition of Organon & Co. This could become the largest overseas acquisition by an Indian pharma company.

US Tariff Risks Add Pressure

Another concern is the new tariff policy under Donald Trump administration. The US plans to impose up to 100% tariffs on patented drug imports from late 2026.

Sun Pharma manufactures many products outside the US, especially in Europe and South Korea. As a result, some drugs, including Ilumya, could face around 15% tariffs, which may hurt profits or force price hikes that could impact market share.

Read More: Best Waste Management and Recycling Stocks in April 2026: Va Tech Wabag, Ion Exchange & Others Based on Market Cap.

About Sun Pharma

Sun Pharmaceutical Industries Limited is a global pharmaceutical company based in Mumbai that produces and markets pharmaceutical formulations and active pharmaceutical ingredients across more than 100 countries.

Sun Pharma Share Price Movement

Sun Pharmaceutical Industries share price (NSE: SUNPHARMA)closed at ₹1,651.20 on April 10 at 2:11 pm, falling ₹65.90 or 3.84% for the day. The stock opened at ₹1,699.20 and touched an intraday high of ₹1,700.00 and a low of ₹1,630.40. Over the past year, the stock has moved between a 52-week high of ₹1,851.20 and a 52-week low of ₹1,548.00, while offering a dividend yield of 1% with a quarterly dividend amount of ₹4.13.

Conclusion

Sun Pharma’s recent decline reflects short-term concerns around a large acquisition and rising US tariffs. investors are cautious about debt, competition, and potential earnings pressure in the near term.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.